Browse treatments

…s, researchers, and health system leaders, future directions in prehabilitation are likely to span a wide and diverse spectrum. Currently, few …

…rdial infarction rates were comparable at all follow-up points. TAVR markedly reduced new-onset or worsening atrial fibrillation (AF…

…icantly improved wound healing rates vs standard of care (SOC). Placenta-derived products showed the greatest efficacy (OR 7.85 (95% credible interval (C…

…lity of life was comparable between the treatment strategies. A non-operative treatment strategy was associated with lower costs, but longer time in hospital, m…

…nctioning was paramount, with surgery seeming unnecessary while medical therapy is effective enough to maintain normal activities, but preferen…

…y, because guideline recommendations often focused on adjusting treatment for individual coexisting conditions rather than considering cl…

…ceptibles), resulting in an underestimation of the true risk of hormone therapy. The comparison between initiators and non-initiators of treatm…

…of the hernia internal ring is essential to prevent recurrence. TPLIS requires extended follow-up to detect possible late recurrence.…

…en 2020-2023 and received chemo/IO. Among patients treated with immunotherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalum…

…s in our study’s cohort had higher HbA1c and were more often on antihypertensive treatment. Both these variables were independently associated with risk o…

…received PM+ alone, 31 received ADT alone and 104 received both PM+ and ADT. The total cost of introducing operations throughout Ne…

…2.6% to 36.4%) for TEVAR and 19.9% (95% CI: 15.6% to 25.2%) for iMT (p=0.99).All-cause mortality was 4.4% (95% CI: 1.4% to 13.6%) f…